Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 19/20 | 0.57 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.57 |
| ▸ | MMP3 | P08254 | 1/20 | 0.57 |
| ▸ | MMP7 | P09237 | 1/20 | 0.57 |
| ▸ | ADAMTS1 | Q9UHI8 | 1/20 | 0.57 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.57 |
| ▸ | MMP13 | P45452 | 3/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6023359 | 0.92 | ADAM17 (0.57) | ADAM17ADAMTS4MMP3MMP7ADAMTS1 | |
| SCHEMBL6023631 | 0.89 | ADAM17 (0.63) | ADAM17MMP13 | |
| SCHEMBL6023092 | 0.87 | ADAM17 (0.47) | ADAM17ADAMTS4MMP3MMP7ADAMTS1 | |
| SCHEMBL6023001 | 0.87 | ADAM17 (0.58) | ADAM17ADAMTS4MMP3MMP7ADAMTS1 | |
| SCHEMBL6022611 | 0.82 | ADAM17 (0.54) | ADAM17ADAMTS4MMP3MMP7ADAMTS1 | |
| SCHEMBL6789215 | 0.80 | ADAM17 (0.68) | ADAM17MMP13 | |
| SCHEMBL7044984 | 0.80 | ADAM17 (0.55) | ADAM17ADAMTS4MMP3MMP7ADAMTS1 | |
| SCHEMBL6023821 | 0.80 | ADAM17 (0.56) | ADAM17ADAMTS4MMP3MMP7ADAMTS1 | |
| SCHEMBL6023172 | 0.78 | ADAM17 (0.54) | ADAM17ADAMTS4MMP3MMP7ADAMTS1 | |
| SCHEMBL6784719 | 0.77 | ADAM17 (0.66) | ADAM17MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7125870-B2 | Isoxazoline derivatives as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-10-24 | — | — | US | claimed |
| US-20040122005-A1 | Isoxazoline derivatives as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme | BRISTOL-MYERS SQUIBB COMPANY | 2004-06-24 | — | — | US | claimed |
| US-7125870-B2 | Isoxazoline derivatives as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122005-A1 | Isoxazoline derivatives as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme | MMP2, MMP1, MMP9 | ADAM17 5/4885ADAMTS4 28/4885MMP3 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.